<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01585961</url>
  </required_header>
  <id_info>
    <org_study_id>ThermoCool SF Phase IV</org_study_id>
    <nct_id>NCT01585961</nct_id>
  </id_info>
  <brief_title>NAVISTAR® THERMOCOOL® SF Catheter: Observational Study</brief_title>
  <acronym>SFAF</acronym>
  <official_title>NAVISTAR® THERMOCOOL® SF Catheter: Observational Study in a Younger and Older Drug Refractory, Recurrent, Symptomatic Paroxysmal AF Population</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biosense Webster, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biosense Webster, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, interventional, observational, unblinded, single-arm, multicenter
      registry of younger and older subjects with drug refractory, recurrent, symptomatic
      paroxysmal atrial fibrillation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is to measure the &quot;real-world&quot; acute procedural outcomes (procedural efficiency,
      acute safety, and effectiveness at one year) associated with use of the NAVISTAR® THERMOCOOL®
      SF Catheter in a clinical setting in subjects with drug refractory, recurrent symptomatic
      paroxysmal atrial fibrillation.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2012</start_date>
  <completion_date type="Actual">July 2014</completion_date>
  <primary_completion_date type="Actual">July 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Total Fluoroscopy Time</measure>
    <time_frame>Day 0 (procedure)</time_frame>
    <description>The fluoroscopy time will be measured for each phase (access, mapping, ablation, and validation) of the procedure and summed to derive the total time.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total Procedure Time</measure>
    <time_frame>Day 0 (procedure)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Acute Procedural Success</measure>
    <time_frame>Day 0 (procedure)</time_frame>
    <description>Confirmation of entrance and/or exit block across all targeted pulmonary veins.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Number of Radiofrequency (RF) Applications</measure>
    <time_frame>Day 0 (procedure)</time_frame>
    <description>RF applications is defined as the number of times RF energy is delivered during the procedure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Radiofrequency (RF) Time</measure>
    <time_frame>Day 0 (procedure)</time_frame>
    <description>Total RF time is defined as the total time that RF energy is delivered during the procedure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fluid Volume Delivered Via Ablation Catheter</measure>
    <time_frame>Day 0 (procedure)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Repeat Ablations</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-procedure AF Symptoms</measure>
    <time_frame>12 Month Visit</time_frame>
    <description>Symptoms attributed to paroxysmal atrial fibrillation reported at 12 month visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Lost Work Days, Related to AF, at 12 Month Visit</measure>
    <time_frame>12 Month Visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Inpatient Hospital Visit(s) Related to Atrial Fibrillation</measure>
    <time_frame>12 Month Visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Outpatient Emergency Visits Related to Atrial Fibrillation</measure>
    <time_frame>12 Month Visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Atrial Fibrillation Effect on Quality of Life (AFEQT) Total Score</measure>
    <time_frame>Screening to 12 Month Visit</time_frame>
    <description>Change is calculated as 12 month overall AFEQT score minus score at screening. An overall AFEQT score ranges from 0 to 100. A score of 0 corresponds to complete disability (or responding &quot;extremely&quot; limited, difficult or bothersome to all questions answered), while a score of 100 corresponds to no disability (or responding &quot;not at all&quot; limited, difficult or bothersome to all questions answered). Therefore a positive change in score corresponds to improvement in AF symptoms.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">511</enrollment>
  <condition>Atrial Fibrillation</condition>
  <condition>Paroxysmal Arrhythmia</condition>
  <arm_group>
    <arm_group_label>Catheter Ablation</arm_group_label>
    <description>These patients have drug refractory, recurrent, symptomatic paroxysmal atrial fibrillation, are aged 18 years or older, and have provided written informed consent to participate in the study, including consent to undergo catheter ablation with the study device.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Catheter Ablation (NAVISTAR® THERMOCOOL® SF Catheter)</intervention_name>
    <description>Administer anesthesia according to standard EP lab protocol, assess the fluid status of the subject (after each liter of infusate), determine if diuresis is necessary, and treat accordingly.</description>
    <arm_group_label>Catheter Ablation</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Older and younger patients with drug refractory, symptomatic paroxysmal atrial
        fibrillation.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Drug refractory, recurrent, symptomatic paroxysmal atrial fibrillation

          -  Age 18 years or older

          -  Patients must be able and willing to provide written informed consent to participate
             in the study

        Exclusion Criteria:

          -  Atrial fibrillation secondary to electrolyte imbalance, thyroid disease, or reversible
             or non-cardiac cause

          -  Previous ablation for atrial fibrillation

          -  Episodes of atrial fibrillation that last longer than 30 days and are terminated via
             cardioversion

          -  Uncontrolled heart failure, or NYHA Class III or IV heart failure

          -  Documented intra-atrial thrombus or other abnormality on pre-ablation echocardiogram

          -  Contraindication to anticoagulation

          -  Stroke, cardiac surgery, unstable angina, myocardial infarction or percutaneous
             coronary intervention within the past 3 months

          -  Awaiting cardiac transplantation

          -  Heart disease in which corrective surgery is anticipated within 6 months

          -  Enrollment in investigational drug, biologic or device study

          -  Subjects unwilling to comply with protocol or follow-up requirements

          -  Patients who are pregnant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gery Tomassoni, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Central Baptist Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Scott Pollak, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Florida Hospital - Orlando</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andy Tran, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Scottsdale Healthcare Research Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Saumil Oza, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Vincent's Ambulatory Care, Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Steven Compton, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Alaska Heart Institute, LLC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anshul Patel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Joseph's Hospital of Atlanta</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Robert Fishel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>JFK Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kenneth Civello, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cardiovascular Research Foundation of Louisiana</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gaurang Gandhi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bethesda North Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alexandru Costea, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Cincinnati</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sreedhar Billakanty, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Riverside Methodist Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>H. James Wang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Florida Hospital Memorial Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>John Harding, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Central Bucks Specialists, Ltd.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mohammed Khan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Alexian Brothers Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Vijay Jayachandran, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baylor All Saints Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sree Karanam, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lutheran Medical Group, LLC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>M. Craig Delaughter, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Plaza Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mohammad Jazayeri, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bellin Memorial Hospital, Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Abdi Rasekh, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Texas Heart Institute at St. Luke's Episcopal Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Scott Allison, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Heart Center Research, LLC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alexander Mazur, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Iowa Hospital &amp; Clinics</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dhanunjaya Lakkireddy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Kansas Hospitals</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alan Wimmer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Luke's Hospital Mid American Heart Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ali Hamzei, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Scripps Clinical Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Shalin Shah, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Largo Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael Kutayli, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bryan LGH Heart Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>John Mandrola, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baptist Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stuart Beldner, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>North Shore University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Joshua Moss, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Chicago</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Greg Bashian, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centennial Heart</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Patrick Whalen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt Heart and Vascular Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Angelo Biviano, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>New York Presbyterian Hospital, Columbia University Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hussam Abuissa, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Cardiac Center of Creighton University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sumeet Mainigi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Albert Einstein Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Charles Athill, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>San Diego Cardiac Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Edward Gerstenfeld, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UCSF Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael Chisner, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cardiology Associates of Savannah</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Vijendra Swarup, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Arizona Heart Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ziad Issa, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Prairie Education and Research Cooperative</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tariq Salam, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cardiac Study Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sung Lee, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington Adventist Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>M. Magdy Migeed, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Genesis Healthcare Systems</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jonathan Sussman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Morristown Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bengt Herweg, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tampa General Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pierce Vatterott, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>United Heart and Vascular Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Heart Center Research, LLC</name>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <zip>35801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alaska Heart Institute, LLC</name>
      <address>
        <city>Anchorage</city>
        <state>Alaska</state>
        <zip>99508</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arizona Heart Hospital</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scottsdale Healthcare Research Institute</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scripps Clinical Research</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Diego Cardiac Center</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSF Medical Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JFK Medical Center</name>
      <address>
        <city>Atlantis</city>
        <state>Florida</state>
        <zip>33462</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Hospital Memorial Medical Center</name>
      <address>
        <city>Daytona Beach</city>
        <state>Florida</state>
        <zip>32117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Vincent's Ambulatory Care, Inc.</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Largo Medical Center</name>
      <address>
        <city>Largo</city>
        <state>Florida</state>
        <zip>33774</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Hospital - Orlando</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tampa General Hospital</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Joseph's Hospital of Atlanta</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiology Associates of Savannah</name>
      <address>
        <city>Savannah</city>
        <state>Georgia</state>
        <zip>31419</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alexian Brothers Medical Center</name>
      <address>
        <city>Elk Grove Village</city>
        <state>Illinois</state>
        <zip>60007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prairie Education and Research Cooperative</name>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <zip>62701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lutheran Medical Group, LLC</name>
      <address>
        <city>Fort Wayne</city>
        <state>Indiana</state>
        <zip>46804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Iowa Hospital &amp; Clinics</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>55242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kansas Hospitals</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Baptist Hospital</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baptist Hospital</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiovascular Research Foundation of Louisiana</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70808</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington Adventist Hospital</name>
      <address>
        <city>Takoma Park</city>
        <state>Maryland</state>
        <zip>20912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>United Heart and Vascular Clinic</name>
      <address>
        <city>St. Paul</city>
        <state>Minnesota</state>
        <zip>55102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Luke's Mid American Heart Institute</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bryan LGH Heart Institute</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Cardiac Center of Creighton University</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Morristown Medical Center</name>
      <address>
        <city>Morristown</city>
        <state>New Jersey</state>
        <zip>07960</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Shore University Hospital</name>
      <address>
        <city>Manhasset</city>
        <state>New York</state>
        <zip>11030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Presbyterian Hospital, Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bethesda North Hospital</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Riverside Methodist Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Genesis Healthcare Systems</name>
      <address>
        <city>Zanesville</city>
        <state>Ohio</state>
        <zip>43701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Bucks Specialists, LTD</name>
      <address>
        <city>Doylestown</city>
        <state>Pennsylvania</state>
        <zip>18901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albert Einstein Medical Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centennial Heart</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt Heart and Vascular Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232-8802</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor All Saints Medical Center</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Plaza Medical Center</name>
      <address>
        <city>Grapevine</city>
        <state>Texas</state>
        <zip>76501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Heart Institute at St. Luke's Episcopal Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiac Study Center</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bellin Memorial Hospital, Inc.</name>
      <address>
        <city>Green Bay</city>
        <state>Wisconsin</state>
        <zip>54301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 14, 2012</study_first_submitted>
  <study_first_submitted_qc>April 25, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 26, 2012</study_first_posted>
  <results_first_submitted>January 13, 2015</results_first_submitted>
  <results_first_submitted_qc>January 20, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 26, 2015</results_first_posted>
  <last_update_submitted>January 20, 2015</last_update_submitted>
  <last_update_submitted_qc>January 20, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 26, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Symptomatic paroxysmal</keyword>
  <keyword>Atrial fibrillation</keyword>
  <keyword>Observational</keyword>
  <keyword>Acute procedural outcomes</keyword>
  <keyword>Ablation</keyword>
  <keyword>Drug refractory</keyword>
  <keyword>Arrhythmia Recurrent</keyword>
  <keyword>Symptomatic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Catheter Ablation</title>
          <description>These patients have drug refractory, recurrent, symptomatic paroxysmal atrial fibrillation, are aged 18 years or older, and are able and willing to provide written informed consent to participate in the study.
Catheter Ablation (NAVISTAR® THERMOCOOL® SF Catheter): Administer anesthesia according to standard EP lab protocol, assess the fluid status of the subject (after each liter of infusate), determine if diuresis is necessary, and treat accordingly.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="511"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Safety</title>
              <participants_list>
                <participants group_id="P1" count="508">Patients ablated with study catheter</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="478"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Decision to use non-study catheter</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Ablation cancelled for slow-heal wound</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Enrolled patients</population>
      <group_list>
        <group group_id="B1">
          <title>Catheter Ablation</title>
          <description>These patients have drug refractory, recurrent, symptomatic paroxysmal atrial fibrillation, are aged 18 years or older, and are able and willing to provide written informed consent to participate in the study.
Catheter Ablation (NAVISTAR® THERMOCOOL® SF Catheter): Administer anesthesia according to standard EP lab protocol, assess the fluid status of the subject (after each liter of infusate), determine if diuresis is necessary, and treat accordingly.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="511"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="265"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="246"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62.0" spread="11.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="194"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="317"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="494"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="477"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="511"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Total Fluoroscopy Time</title>
        <description>The fluoroscopy time will be measured for each phase (access, mapping, ablation, and validation) of the procedure and summed to derive the total time.</description>
        <time_frame>Day 0 (procedure)</time_frame>
        <population>Subset of Safety Population with non-missing endpoint data.</population>
        <group_list>
          <group group_id="O1">
            <title>Catheter Ablation</title>
            <description>These patients have drug refractory, recurrent, symptomatic paroxysmal atrial fibrillation, are aged 18 years or older, and are able and willing to provide written informed consent to participate in the study.
Catheter Ablation (NAVISTAR® THERMOCOOL® SF Catheter): Administer anesthesia according to standard EP lab protocol, assess the fluid status of the subject (after each liter of infusate), determine if diuresis is necessary, and treat accordingly.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Fluoroscopy Time</title>
          <description>The fluoroscopy time will be measured for each phase (access, mapping, ablation, and validation) of the procedure and summed to derive the total time.</description>
          <population>Subset of Safety Population with non-missing endpoint data.</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="506"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.4" spread="21.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Total Procedure Time</title>
        <time_frame>Day 0 (procedure)</time_frame>
        <population>Subset of Safety Population with non-missing endpoint data.</population>
        <group_list>
          <group group_id="O1">
            <title>Catheter Ablation</title>
            <description>These patients have drug refractory, recurrent, symptomatic paroxysmal atrial fibrillation, are aged 18 years or older, and are able and willing to provide written informed consent to participate in the study.
Catheter Ablation (NAVISTAR® THERMOCOOL® SF Catheter): Administer anesthesia according to standard EP lab protocol, assess the fluid status of the subject (after each liter of infusate), determine if diuresis is necessary, and treat accordingly.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Procedure Time</title>
          <population>Subset of Safety Population with non-missing endpoint data.</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="507"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="169.8" spread="82.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Acute Procedural Success</title>
        <description>Confirmation of entrance and/or exit block across all targeted pulmonary veins.</description>
        <time_frame>Day 0 (procedure)</time_frame>
        <population>Safety population</population>
        <group_list>
          <group group_id="O1">
            <title>Catheter Ablation</title>
            <description>These patients have drug refractory, recurrent, symptomatic paroxysmal atrial fibrillation, are aged 18 years or older, and are able and willing to provide written informed consent to participate in the study.
Catheter Ablation (NAVISTAR® THERMOCOOL® SF Catheter): Administer anesthesia according to standard EP lab protocol, assess the fluid status of the subject (after each liter of infusate), determine if diuresis is necessary, and treat accordingly.</description>
          </group>
        </group_list>
        <measure>
          <title>Acute Procedural Success</title>
          <description>Confirmation of entrance and/or exit block across all targeted pulmonary veins.</description>
          <population>Safety population</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="508"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="488"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Number of Radiofrequency (RF) Applications</title>
        <description>RF applications is defined as the number of times RF energy is delivered during the procedure.</description>
        <time_frame>Day 0 (procedure)</time_frame>
        <population>Subset of Safety Population with non-missing endpoint data.</population>
        <group_list>
          <group group_id="O1">
            <title>Catheter Ablation</title>
            <description>These patients have drug refractory, recurrent, symptomatic paroxysmal atrial fibrillation, are aged 18 years or older, and are able and willing to provide written informed consent to participate in the study.
Catheter Ablation (NAVISTAR® THERMOCOOL® SF Catheter): Administer anesthesia according to standard EP lab protocol, assess the fluid status of the subject (after each liter of infusate), determine if diuresis is necessary, and treat accordingly.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Number of Radiofrequency (RF) Applications</title>
          <description>RF applications is defined as the number of times RF energy is delivered during the procedure.</description>
          <population>Subset of Safety Population with non-missing endpoint data.</population>
          <units>number of applications</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="489"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.0" spread="35.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Radiofrequency (RF) Time</title>
        <description>Total RF time is defined as the total time that RF energy is delivered during the procedure.</description>
        <time_frame>Day 0 (procedure)</time_frame>
        <population>Subset of Safety Population with non-missing endpoint data.</population>
        <group_list>
          <group group_id="O1">
            <title>Catheter Ablation</title>
            <description>These patients have drug refractory, recurrent, symptomatic paroxysmal atrial fibrillation, are aged 18 years or older, and are able and willing to provide written informed consent to participate in the study.
Catheter Ablation (NAVISTAR® THERMOCOOL® SF Catheter): Administer anesthesia according to standard EP lab protocol, assess the fluid status of the subject (after each liter of infusate), determine if diuresis is necessary, and treat accordingly.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Radiofrequency (RF) Time</title>
          <description>Total RF time is defined as the total time that RF energy is delivered during the procedure.</description>
          <population>Subset of Safety Population with non-missing endpoint data.</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="505"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.9" spread="37.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fluid Volume Delivered Via Ablation Catheter</title>
        <time_frame>Day 0 (procedure)</time_frame>
        <population>Subset of Safety Population with non-missing endpoint data.</population>
        <group_list>
          <group group_id="O1">
            <title>Catheter Ablation</title>
            <description>These patients have drug refractory, recurrent, symptomatic paroxysmal atrial fibrillation, are aged 18 years or older, and are able and willing to provide written informed consent to participate in the study.
Catheter Ablation (NAVISTAR® THERMOCOOL® SF Catheter): Administer anesthesia according to standard EP lab protocol, assess the fluid status of the subject (after each liter of infusate), determine if diuresis is necessary, and treat accordingly.</description>
          </group>
        </group_list>
        <measure>
          <title>Fluid Volume Delivered Via Ablation Catheter</title>
          <population>Subset of Safety Population with non-missing endpoint data.</population>
          <units>mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="495"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="974.2" spread="481.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Repeat Ablations</title>
        <time_frame>1 year</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Catheter Ablation</title>
            <description>These patients have drug refractory, recurrent, symptomatic paroxysmal atrial fibrillation, are aged 18 years or older, and are able and willing to provide written informed consent to participate in the study.
Catheter Ablation (NAVISTAR® THERMOCOOL® SF Catheter): Administer anesthesia according to standard EP lab protocol, assess the fluid status of the subject (after each liter of infusate), determine if diuresis is necessary, and treat accordingly.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Repeat Ablations</title>
          <population>Safety Population</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="508"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Post-procedure AF Symptoms</title>
        <description>Symptoms attributed to paroxysmal atrial fibrillation reported at 12 month visit</description>
        <time_frame>12 Month Visit</time_frame>
        <population>Subset of Safety Population with non-missing endpoint data.</population>
        <group_list>
          <group group_id="O1">
            <title>Catheter Ablation</title>
            <description>These patients have drug refractory, recurrent, symptomatic paroxysmal atrial fibrillation, are aged 18 years or older, and are able and willing to provide written informed consent to participate in the study.
Catheter Ablation (NAVISTAR® THERMOCOOL® SF Catheter): Administer anesthesia according to standard EP lab protocol, assess the fluid status of the subject (after each liter of infusate), determine if diuresis is necessary, and treat accordingly.</description>
          </group>
        </group_list>
        <measure>
          <title>Post-procedure AF Symptoms</title>
          <description>Symptoms attributed to paroxysmal atrial fibrillation reported at 12 month visit</description>
          <population>Subset of Safety Population with non-missing endpoint data.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="470"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="155"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Lost Work Days, Related to AF, at 12 Month Visit</title>
        <time_frame>12 Month Visit</time_frame>
        <population>Subset of Safety Population with non-missing endpoint data.</population>
        <group_list>
          <group group_id="O1">
            <title>Catheter Ablation</title>
            <description>These patients have drug refractory, recurrent, symptomatic paroxysmal atrial fibrillation, are aged 18 years or older, and are able and willing to provide written informed consent to participate in the study.
Catheter Ablation (NAVISTAR® THERMOCOOL® SF Catheter): Administer anesthesia according to standard EP lab protocol, assess the fluid status of the subject (after each liter of infusate), determine if diuresis is necessary, and treat accordingly.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Lost Work Days, Related to AF, at 12 Month Visit</title>
          <population>Subset of Safety Population with non-missing endpoint data.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="477"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Inpatient Hospital Visit(s) Related to Atrial Fibrillation</title>
        <time_frame>12 Month Visit</time_frame>
        <population>Population with Utilization Data</population>
        <group_list>
          <group group_id="O1">
            <title>Catheter Ablation</title>
            <description>These patients have drug refractory, recurrent, symptomatic paroxysmal atrial fibrillation, are aged 18 years or older, and are able and willing to provide written informed consent to participate in the study.
Catheter Ablation (NAVISTAR® THERMOCOOL® SF Catheter): Administer anesthesia according to standard EP lab protocol, assess the fluid status of the subject (after each liter of infusate), determine if diuresis is necessary, and treat accordingly.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Inpatient Hospital Visit(s) Related to Atrial Fibrillation</title>
          <population>Population with Utilization Data</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="489"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Outpatient Emergency Visits Related to Atrial Fibrillation</title>
        <time_frame>12 Month Visit</time_frame>
        <population>Population with Utilization Data</population>
        <group_list>
          <group group_id="O1">
            <title>Catheter Ablation</title>
            <description>These patients have drug refractory, recurrent, symptomatic paroxysmal atrial fibrillation, are aged 18 years or older, and are able and willing to provide written informed consent to participate in the study.
Catheter Ablation (NAVISTAR® THERMOCOOL® SF Catheter): Administer anesthesia according to standard EP lab protocol, assess the fluid status of the subject (after each liter of infusate), determine if diuresis is necessary, and treat accordingly.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Outpatient Emergency Visits Related to Atrial Fibrillation</title>
          <population>Population with Utilization Data</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="489"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Atrial Fibrillation Effect on Quality of Life (AFEQT) Total Score</title>
        <description>Change is calculated as 12 month overall AFEQT score minus score at screening. An overall AFEQT score ranges from 0 to 100. A score of 0 corresponds to complete disability (or responding “extremely” limited, difficult or bothersome to all questions answered), while a score of 100 corresponds to no disability (or responding “not at all” limited, difficult or bothersome to all questions answered). Therefore a positive change in score corresponds to improvement in AF symptoms.</description>
        <time_frame>Screening to 12 Month Visit</time_frame>
        <population>Subset of Safety Population with non-missing AFEQT data at 12 months.</population>
        <group_list>
          <group group_id="O1">
            <title>Catheter Ablation</title>
            <description>These patients have drug refractory, recurrent, symptomatic paroxysmal atrial fibrillation, are aged 18 years or older, and are able and willing to provide written informed consent to participate in the study.
Catheter Ablation (NAVISTAR® THERMOCOOL® SF Catheter): Administer anesthesia according to standard EP lab protocol, assess the fluid status of the subject (after each liter of infusate), determine if diuresis is necessary, and treat accordingly.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Atrial Fibrillation Effect on Quality of Life (AFEQT) Total Score</title>
          <description>Change is calculated as 12 month overall AFEQT score minus score at screening. An overall AFEQT score ranges from 0 to 100. A score of 0 corresponds to complete disability (or responding “extremely” limited, difficult or bothersome to all questions answered), while a score of 100 corresponds to no disability (or responding “not at all” limited, difficult or bothersome to all questions answered). Therefore a positive change in score corresponds to improvement in AF symptoms.</description>
          <population>Subset of Safety Population with non-missing AFEQT data at 12 months.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="462"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.0" spread="23.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Procedure through 7 days post-procedure</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Catheter Ablation</title>
          <description>These patients have drug refractory, recurrent, symptomatic paroxysmal atrial fibrillation, are aged 18 years or older, and are able and willing to provide written informed consent to participate in the study.
Catheter Ablation (NAVISTAR® THERMOCOOL® SF Catheter): Administer anesthesia according to standard EP lab protocol, assess the fluid status of the subject (after each liter of infusate), determine if diuresis is necessary, and treat accordingly.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="63" subjects_at_risk="508"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="508"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Cardiac tamponade</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Atrial tachycardia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Cardiac perforation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Sick sinus syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="508"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Gastrointestinal hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="508"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Catheter site hematoma</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Device difficult to use (foley)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="508"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="508"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Subdural hematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Vascular pseudoaneurysm</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="508"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>International normalized ratio decreased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Electrocardiogram ST segment depression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Hematocrit decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Hemoglobin decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="508"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="508"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Transient global amnesia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="508"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hematuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="508"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Dyspnea exertional</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="508"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Femoral artery aneurysm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Intra-abdominal hematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="508"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="79" subjects_at_risk="508"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="508"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="508"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="508"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Catheter site hematoma</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="508"/>
              </event>
              <event>
                <sub_title>Catheter site hemorrhage</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="508"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Fluid Overload</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="508"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="508"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="508"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="508"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="508"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is an agreement between the Principal Investigator (PI)/Institution and the Sponsor (or its agents) that restricts the PI's rights to discuss, present, or publish trial results after the trial is completed. Please contact Biosense Webster for additional information.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Ellen Harris, Project Manager, Clinical Operations</name_or_title>
      <organization>Biosense Webster</organization>
      <phone>909-839-7376</phone>
      <email>eharris8@its.jnj.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

